ZYMOGENETICS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 323
- Market Cap
- -
- Website
- http://www.zymogenetics.com
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 600
- Registration Number
- NCT01001754
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 30
- Registration Number
- NCT00859547
- Locations
- ๐บ๐ธ
Arizona Burn Center, Phoenix, Arizona, United States
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 31
- Registration Number
- NCT00813904
- Locations
- ๐บ๐ธ
Tuscon Orthopaedic Institute, Tuscon, Arizona, United States
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
- Conditions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2009-10-07
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 56
- Registration Number
- NCT00565539
- Locations
- ๐บ๐ธ
St. Luke's Advanced Liver Therapies, Houston, Texas, United States
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธUniversity Hospital (UMDNJ), Newark, New Jersey, United States
Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 234
- Registration Number
- NCT00491608
- Locations
- ๐บ๐ธ
Huntington Memorial Hospital, Pasadena, California, United States
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2009-05-27
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 52
- Registration Number
- NCT00389285
- Locations
- ๐บ๐ธ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธUniversity of Alabama, Birmingham, Alabama, United States
๐บ๐ธPremiere Oncology of Arizona, Scottsdale, Arizona, United States
Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 72
- Registration Number
- NCT00371215
- Locations
- ๐บ๐ธ
Richard M. Fairbanks Burn Center, Wishard Hospital, Indianapolis, Indiana, United States
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 23
- Registration Number
- NCT00347971
- Locations
- ๐บ๐ธ
University of California, Los Angeles, Los Angeles, California, United States
Study of Recombinant Human Thrombin for Bleeding During Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 401
- Registration Number
- NCT00245336
- Locations
- ๐บ๐ธ
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธHuntington Memorial Hospital, Pasadena, California, United States
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 43
- Registration Number
- NCT00095108
- Locations
- ๐บ๐ธ
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธUniversity of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States